Form 4 for BNGO Bionano Genomics, Inc.
Accepted 2024-03-05 00:00:00 ET · period of report 2024-02-15 · accession 0001415889-24-006809 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-05 | 2024-02-15 | BNGO | Holmlin R. Erik | Pres AND CEO, Dir | F - Tax | $1.27 | -3,073 | 77.7K | -4% | -$3,903 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-15 | F | D | 3,073 | $1.27 | 77,663 | D | — | — | (F1) The reporting person is reporting the withholding by the Issuer of an aggregate of 3,073 shares of common stock in connection with shares that vested on February 15, 2024 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. (F2) On August 4, 2023, the common stock of Bionano Genomics, Inc. split 1-for-10, resulting in the reporting person's ownership of 730,350 less shares of common stock (725,827 less shares held directly and 4,523 less shares held indirectly). (F3) Includes 89 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan on June 12, 2023. |